Advertisement

Topics

New FDA/EMA rare diseases and patient engagement clusters underway

17:08 EDT 18 Oct 2016 | FDA Voice

By: Jonathan Goldsmith, M.D., FACP, and Sandy Kweder, M.D., RADM (Ret.) US Public Health Service Drug development and approval happens across the globe and we at FDA strive to collaborate with other countries and international regulatory agencies to ensure public … Continue reading

Original Article: New FDA/EMA rare diseases and patient engagement clusters underway

NEXT ARTICLE

More From BioPortfolio on "New FDA/EMA rare diseases and patient engagement clusters underway"

Quick Search
Advertisement
 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...